Biotechnology News and Research

RSS

IRB researchers identify dual role of p38 protein in colon cancer

A team headed by Angel R. Nebreda at the Institute for Research in Biomedicine identifies a dual role of the p38 protein in colon cancer. The study demonstrates that, on the one hand, p38 is important for the optimal maintenance of the epithelial barrier that protects the intestine against toxic agents, thus contributing to decreased tumour development.

28 Mar 2014

Baxter plans to create two independent global healthcare companies

Baxter International Inc. today announced plans to create two separate, independent global healthcare companies -- one focused on developing and marketing innovative biopharmaceuticals and the other on life-saving medical products. Both will be global leaders in their respective markets.

From Baxter International Inc. 27 Mar 2014

pSivida resubmits New Drug Application for ILUVIEN

pSivida Corp., a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the New Drug Application for ILUVIEN for the treatment of chronic Diabetic Macular Edema has been resubmitted to the U.S. Food and Drug Administration (FDA).

27 Mar 2014

2014 Biotech China to be held on 14-16 May in Nanjing, China

Biotech China, the first major Chinese biotech exhibition and conference, will hold the 2014 Biotech China on 14-16th May, 2014 in Nanjing, China.

27 Mar 2014

Researchers decode effects of antimicrobial peptide on bacterial cells

The team of Julia Bandow, who heads the RUB's Junior Research Group Microbial Antibiotic Research, has been studying the MP196 peptide as a representative of a group of very small positively charged peptides that consist of some four to ten amino acids.

27 Mar 2014

Insmed reports results from ARIKAYCE phase 2 trial for treatment resistant NTM lung infections

Insmed Incorporated today reported results from the Company's phase 2 clinical trial of ARIKAYCETM, or liposomal amikacin for inhalation, for the treatment of patients with treatment resistant nontuberculous mycobacterial (NTM) lung infections.

26 Mar 2014

New international partnership aims to increase wheat yields by 50% by 2034

A new international partnership aims to increase wheat yields by 50 percent by 2034. This will address demand for wheat - one of the world's most important crops - that is growing much faster than production.

26 Mar 2014

United Therapeutics' Remodulin Injection gets approval in Japan for PAH treatment

United Therapeutics Corporation today announced that Japan's Ministry of Health, Labour and Welfare has granted approval for Remodulin (treprostinil) Injection for the treatment of pulmonary arterial hypertension (PAH) by subcutaneous and intravenous administration.

26 Mar 2014

e-Therapeutics obtains MHRA approval to recommence recruitment for ETS2101 phase Ia trial

e-Therapeutics plc announces today that it has received approval from MHRA to recommence recruitment of new patients into its ETS2101 phase Ia solid tumours trial being conducted at three centres in the UK.

26 Mar 2014

Precision for Medicine announces acquisition of Hobart Group Holdings

Precision for Medicine, Inc., formed in 2012 to support next generation approaches to drug development and commercialization, announces the acquisition of Hobart Group Holdings, LLC, a leading market access firm. With this addition, Precision for Medicine has established the foundation for its next phase of growth in providing integrated solutions focused on demonstrating value in the era of precision medicine.

25 Mar 2014

European Commission approves Exelixis' COMETRIQ for treatment of progressive, metastatic MTC

Exelixis, Inc. today announced that the European Commission has approved COMETRIQ (cabozantinib) for the treatment of adult patients with progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma (MTC).

25 Mar 2014

Democratic lawmakers ask hepatitis C drugmaker to justify price

A new drug to treat hepatitis C that costs $1,000 a pill has caused rising concern among insurers and state Medicaid programs. It has now also spurred interest from Democratic congressmen whose queries about the drug prompted a sell-off in biotechnology stocks on Friday. Three Democratic members of the House Energy and Commerce Committee have demanded that Gilead Sciences, the developer, justify the price of its drug, which is called Sovaldi (Pollack, 3/21).

25 Mar 2014

Researchers develop one-step analysis for detecting tumor markers in blood

Benign growth, or cancer? Tumor markers in the blood help determine whether the patient is afflicted with a malign tumor and whether it is excreting markers more vigorously - involving highly specific proteins. An increased concentration in the blood provides one indication of the disease for physicians. However, it has been quite expensive in time and effort to detect the markers thus far. This is because all kinds of molecules and proteins are teeming in the blood. To be able to detect a single specific one, doctors must first separate and purify the blood in several steps, and then isolate the marker they are searching for from the rest of the molecules.

25 Mar 2014

Transgene raises €65.5M via two-step capital increase

Transgene SA, a French biopharmaceutical company focused on discovering, developing and manufacturing targeted immunotherapies for the treatment of cancer and infectious diseases, announces that it has raised a total of €65.5 million via a two-step capital increase.

25 Mar 2014

Agios initiates AG-120 Phase 1 study to evaluate advanced solid tumors with IDH1 mutation

Agios Pharmaceuticals, Inc., a leader in the fields of cancer metabolism and inborn errors of metabolism, today announced dose administration for the first patient in a Phase 1 study of AG-120 in patients with advanced solid tumors with an isocitrate dehydrogenase-1 (IDH1) mutation.

25 Mar 2014

Marina Cavazzana, Adrian J. Thrasher honored with Pioneer Award for gene therapy

Marina Cavazzana, MD, PhD, Paris Descartes University, France and Adrian J. Thrasher, MD, PhD, University College London Institute of Child Health, UK, have been honored with the Pioneer Award for basic and clinical gene therapy for immunodeficiency disorders.

25 Mar 2014

AMRI signs definitive agreement to acquire all outstanding shares of Cedarburg Pharmaceuticals

AMRI today announced that it has signed a definitive agreement to acquire all the outstanding shares of Cedarburg Pharmaceuticals, Inc. for $38.2 million in cash.

24 Mar 2014

Patrys provides update on development programme for anti-cancer product, PAT-LM1

Patrys Limited, a clinical stage biotechnology company, is pleased to provide an update on the development programme for anti-cancer product, PAT-LM1.

24 Mar 2014

First Edition: March 24, 2013

Today's early morning highlights from the major news organizations examine the final week for health law enrollment, the Supreme Court case this week about the law's contraceptive mandate and the fourth anniversary of the enactment of the controversial overhaul.

24 Mar 2014

FDA approves Xolair for treatment of chronic idiopathic urticaria

Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration approved Xolair (omalizumab) for the treatment of chronic idiopathic urticaria, a form of chronic hives.

24 Mar 2014

Biotechnology News and Research

IRB researchers identify dual role of p38 protein in colon cancer

Baxter plans to create two independent global healthcare companies

pSivida resubmits New Drug Application for ILUVIEN

2014 Biotech China to be held on 14-16 May in Nanjing, China

Researchers decode effects of antimicrobial peptide on bacterial cells

Insmed reports results from ARIKAYCE phase 2 trial for treatment resistant NTM lung infections

New international partnership aims to increase wheat yields by 50% by 2034

United Therapeutics' Remodulin Injection gets approval in Japan for PAH treatment

e-Therapeutics obtains MHRA approval to recommence recruitment for ETS2101 phase Ia trial

Precision for Medicine announces acquisition of Hobart Group Holdings

European Commission approves Exelixis' COMETRIQ for treatment of progressive, metastatic MTC

Democratic lawmakers ask hepatitis C drugmaker to justify price

Researchers develop one-step analysis for detecting tumor markers in blood

Transgene raises €65.5M via two-step capital increase

Agios initiates AG-120 Phase 1 study to evaluate advanced solid tumors with IDH1 mutation

Marina Cavazzana, Adrian J. Thrasher honored with Pioneer Award for gene therapy

AMRI signs definitive agreement to acquire all outstanding shares of Cedarburg Pharmaceuticals

Patrys provides update on development programme for anti-cancer product, PAT-LM1

First Edition: March 24, 2013

FDA approves Xolair for treatment of chronic idiopathic urticaria

Industry Focus eBook - Biotechnology (4th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News